ICCC (ImmuCell) YoY EBITDA Growth: 87.32% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
51 GF Score
Price $10.00
GF Value $6.92
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ImmuCell YoY EBITDA Growth?

ImmuCell ICCC -1.00% 51 YoY EBITDA Growth is 87.32% as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 51/100 and a GF Value™ of $6.92 (Significantly Overvalued). The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. ImmuCell's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 87.32%.

ImmuCell's EBITDA per Share for the three months ended in Jun. 2026 was $0.27.

ImmuCell YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for ImmuCell's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell YoY EBITDA Growth Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.33 -87.36 -846.67 138.99 80.92

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 254.35 453.85 -252.03 14.00 87.32
ICCC
51GF Score
ImmuCell Corp ICCC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

ImmuCell's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.237-0.131)/ | 0.131 |
=80.92 %

ImmuCell's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.266-0.142)/ | 0.142 |
=87.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 87.32% mean?
ImmuCell (ICCC) has a YoY EBITDA Growth of 87.32% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for ImmuCell and its competitors.
Is ImmuCell's YoY EBITDA Growth too high?
ImmuCell's current YoY EBITDA Growth is 87.32%. Overall, ImmuCell has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's YoY EBITDA Growth compare to COYA and ENTX?
ImmuCell's YoY EBITDA Growth of 87.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for ImmuCell and its competitors. ImmuCell's current YoY EBITDA Growth is 87.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.92, compared to a current price of $10.00 — trading 44.5% above its estimated fair value. The current YoY EBITDA Growth is 87.32%. ImmuCell's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For ImmuCell (ICCC), the current YoY EBITDA Growth is 87.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $10.00 is trading 44.5% above its estimated GF Value™ of $6.92. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • YoY EBITDA Growth: 87.32%
  • GF Value™: $6.92 vs. price of $10.00 (44.5% above fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
51GF Score

Get the complete analysis for ICCC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$6.92
GF Value